Cytogen’s Q4 losses shrink

For the full year, Cytogen reported a net loss of $25.7 million, or $0.79 per diluted share in 2007, compared to a net loss of $15.1 million, or $.64 per diluted share in 2006. Product revenues, which were predominately comprised of sales of Quadramet (samarium Sm-153 lexidronam injection), Prostascint (capromab pendetide), and Caphosol, an advanced electrolyte solution for the treatment of oral mucositis and dry mouth, were $5.1 million for the fourth quarter of 2007 compared to $4.5 million for the same period in 2006.

For the full year, total product revenues increased to $20.2 million in 2007 compared to $17.3 million in 2006.